CoChat

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

Open access
Hecht, J. Randolph, Benson, Al B., Vyushkov, Dmitry, Yang, Yingsi, Bendell, Johanna, Verma, Udit · 2017 · The Oncologist
Cited by 134

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Lessons Learned: The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group. The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carcinoma. Background: Simtuzumab, a humanized IgG4 monoclonal antibody to lysyl oxidase-like 2 (LOXL2), blocks desmoplastic reaction in colorectal carcinoma (CRC) cells in vitro. Methods: Patients with metastatic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant CRC were randomized to receive second-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) with either 200 or 700 mg simtuzumab or placebo every 2 weeks in cycles of 28 days. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety were assessed. Results: In total, 249 patients were randomized and treated with FOLFIRI/simtuzumab 700 mg (n = 84), FOLFIRI/simtuzumab 200 mg (n = 85), and FOLFIRI/placebo (n = 80). After a median follow-up of 5.1, 3.8, and 5.5 months, respectively, median PFS for each of the respective treatment groups was 5.5 months (adjusted HR [95% CI], p value versus placebo; 1.32 [0.92, 1.89]; p = .10), 5.4 months (1.45 [1.01, 2.06]; p = .04), and 5.8 months. Median OS was 11.4 months (1.23 [0.80, 1.91]; p = .25), 10.5 months (1.50 [0.98, 2.30]; p = .06), and 16.3 months, respectively. ORR was 11.9%, 5.9%, and 10%, respectively. Simtuzumab was tolerable in metastatic KRAS mutant CRC patients. Conclusion: The addition of simtuzumab to FOLFIRI did not improve clinical outcomes in patients with metastatic KRAS mutant CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2016-0479

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 13

  1. Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 · DOI · Paper page
  2. Armaghany, 2012, Genetic alterations in colorectal cancer, Gastrointest Cancer Res, 5, 19
  3. Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers, Br J Cancer, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
  4. Bremnes, 2011, The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer, J Thorac Oncol, 6, 209, 10.1097/JTO.0b013e3181f8a1bd · DOI · Paper page
  5. Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression, Nature, 432, 332, 10.1038/nature03096 · DOI · Paper page
  6. Fong, 2007, Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors, Genes Chromosomes Cancer, 46, 644, 10.1002/gcc.20444 · DOI
  7. Zaffryar-Eilot, 2013, Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours, Carcinogenesis, 34, 2370, 10.1093/carcin/bgt241 · DOI
  8. Payne, 2007, Paradoxical roles for lysyl oxidases in cancer–a prospect, J Cell Biochem, 101, 1338, 10.1002/jcb.21371 · DOI · Paper page
  9. Hecht, 2015, A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma, J Clin Oncol, 10.1200/jco.2015.33.15_suppl.3537 · DOI
  10. Rodriguez, 2010, Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor, J Biol Chem, 285, 20964, 10.1074/jbc.M109.094136 · DOI · Paper page
  11. Bergen, 2013, The role of LOX and LOXL2 in scar formation after glaucoma surgery, Invest Ophthalmol Vis Sci, 54, 5788, 10.1167/iovs.13-11696 · DOI
  12. Peng, 2009, Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway, Carcinogenesis, 30, 1660, 10.1093/carcin/bgp178 · DOI · Paper page
  13. LoRusso, 2014, Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors, J Clin Oncol, 32, 10.1200/jco.2014.32.3_suppl.554 · DOI

Cited by

See all 134

Metadata

Authors
Hecht, J. R., Benson, A. B., Vyushkov, D., Yang, Y., Bendell, J., & Verma, U.
Venue
The Oncologist
Published
2017-02-28
Volume
22
Issue
3
Pages
243-e23
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2592181184
Cited by
134
References
2
FWCI
3.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. https://app.cochat.ai/papers/10.1634/theoncologist.2016-0479
The paper
Hecht, J. R., Benson, A. B., Vyushkov, D., Yang, Y., Bendell, J., & Verma, U. (2017). A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. The Oncologist. https://doi.org/10.1634/theoncologist.2016-0479

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.